Medications for Obesity: Mechanisms and Applications

被引:28
作者
Bray, George A. [1 ]
机构
[1] Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA
关键词
Sympathomimetic drugs; Lipase inhibitor; Cannabinoid receptor antagonists; Glucagon-like peptide analogues; Seratonin agonist; Multiple amine reuptake inhibitor; IMPROVES GLYCEMIC CONTROL; PLACEBO-CONTROLLED TRIAL; LONG-TERM MAINTENANCE; DECREASES FOOD-INTAKE; LOW-CALORIE DIET; WEIGHT-LOSS; DOUBLE-BLIND; EXENATIDE EXENDIN-4; BODY-WEIGHT; PHARMACOLOGICAL-TREATMENT;
D O I
10.1016/j.ccm.2009.05.014
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
100201 [内科学];
摘要
Medications can significantly increase weight loss compared with placebo in most trials. In general, patients can expect a weight loss of 8% to 10% from baseline provided they adhere to the weight-loss program and take medications regularly. All medications have side effects that need to be considered before initiating treatment, however. For sibutramine, there is an increase in blood pressure and heart rate that may require discontinuation of the drug in a small percentage of patients. For orlistat, the principal side effect is gastrointestinal in origin resulting from the increased activity of the lower bowel. Cannabinoid receptor antagonists, once a promising target, are no longer under study. Other medications are in clinical trials and on their way.
引用
收藏
页码:525 / +
页数:15
相关论文
共 89 条
[1]
Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial [J].
Anderson, JW ;
Greenway, FL ;
Fujioka, K ;
Gadde, KM ;
McKenney, J ;
O'Neil, PM .
OBESITY RESEARCH, 2002, 10 (07) :633-641
[2]
[Anonymous], 2020, WHO Technical Report Series 1004, Annex 9, 2017: World Health Organization
[3]
Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine [J].
Apfelbaum, M ;
Vague, P ;
Ziegler, O ;
Hanotin, C ;
Thomas, F ;
Leutenegger, E .
AMERICAN JOURNAL OF MEDICINE, 1999, 106 (02) :179-184
[4]
Topiramate: Long-term maintenance of weight loss induced by a low-calorie diet in obese subjects [J].
Astrup, A ;
Caterson, I ;
Zelissen, P ;
Guy-Grand, B ;
Carruba, M ;
Levy, B ;
Sun, X ;
Fitchet, M .
OBESITY RESEARCH, 2004, 12 (10) :1658-1669
[5]
Topiramate: A new potential pharmacological treatment for obesity [J].
Astrup, A ;
Toubro, S .
OBESITY RESEARCH, 2004, 12 :167S-173S
[6]
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial [J].
Astrup, Arne ;
Madsbad, Sten ;
Breum, Leif ;
Jensen, Thomas J. ;
Kroustrup, Jens Peter ;
Larsen, Thomas Meinert .
LANCET, 2008, 372 (9653) :1906-1913
[7]
What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions [J].
Avenell, A ;
Brown, TJ ;
McGee, MA ;
Campbell, MK ;
Grant, AM ;
Broom, J ;
Jung, RT ;
Smith, WCS .
JOURNAL OF HUMAN NUTRITION AND DIETETICS, 2004, 17 (04) :293-316
[8]
Predictors of weight loss in adults with topiramate-treated epilepsy [J].
Ben-Menachem, E ;
Axelsen, M ;
Johanson, EH ;
Stagge, A ;
Smith, U .
OBESITY RESEARCH, 2003, 11 (04) :556-562
[9]
Behavior therapy and sibutramine for the treatment of adolescent obesity - A randomized controlled trial [J].
Berkowitz, RI ;
Wadden, TA ;
Tershakovec, AM ;
Cronquist, JL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (14) :1805-1812
[10]
Effects of sibutramine treatment in obese adolescents - A randomized trial [J].
Berkowitz, Robert I. ;
Fujioka, Ken ;
Daniels, Stephen R. ;
Hoppin, Alison G. ;
Owen, Stanford ;
Perry, Arlette C. ;
Sothern, Melinda S. ;
Renz, Cheryl L. ;
Pirner, Mark A. ;
Walch, Julia K. ;
Jasinsky, Olga ;
Hewkin, Ann C. ;
Blakesley, Vicky A. .
ANNALS OF INTERNAL MEDICINE, 2006, 145 (02) :81-90